Nebenwirkungen · Nucala
Nucala 100 mg solution for injection in pre-filled pen Nucala 100 mg solution for injection in pre-filled syringe Nucala 40 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-132574 · Präparat HOS-097252
The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000); and not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T16:02:00Z · SHA-256 297766dd530d777167969a87af3c0ff120dce3cd78dcb8c4ddbec012a3bcb033 · Passage 7f39fdcef7e5373c20d06b97c13f569dcb295d36da4ad7ece6b544a8f9749e16 · Zeichen 2278–2643 im Abschnitt